Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP plus mosunetuzumab as first-line treatment for Richter syndrome
2023-505621-13-00Phase 2Authorised
- Sponsor
- Grupo Español de Leucemia Linfocítica Crónica
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab, cyclophosphamide, doxorubicin, vincristine and prednisone in Richter's syndrome (RS), sponsored by Grupo Español de Leucemia Linfocítica Crónica. Primary endpoint: Complete remission. Planned start May 2024; status: authorised.
02
Drugs
mosunetuzumabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on 2023-505621-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505621-13-00.